[Market Feature] Hans Biomed Shares Rise on Product Diversification and Improved Financial Structure
Hans Biomed's stock price is showing a strong increase of over 14%, driven by factors such as product diversification and improvements in its financial structure.
As of 11:43 a.m. on February 2, Hans Biomed shares were trading at 45,250 won, up 14.56% (5,750 won) from the previous trading day.
On this day, SangSangin Securities issued a "Buy" investment opinion on Hans Biomed and set a target price of 50,000 won. Ha Taegi, a researcher at SangSangin Securities, stated, "Hans Biomed's sales and profits are expected to see full-fledged growth next year," adding, "Although there may be a short-term correction due to the recent sharp rise in the stock price, the long-term upward trend is likely to continue, reflecting the company's potential growth value."
He also noted, "Since October last year, sales of the ECM-based skin booster Cellrdiem have grown rapidly. With the re-launch of the Bounce breast implant scheduled for March-April this year and entry into the Chinese bone graft market, overall company sales are expected to increase significantly."
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
There are also signs that the company's financial structure is improving. Researcher Ha explained, "Although the company paid approximately 23 billion won in damages in a civil lawsuit in the second half of last year, it resolved this with 10 billion won in existing funds, 17 billion won raised through the sale of treasury shares, and 18.6 billion won from a paid-in capital increase. The company is believed to have about 20 billion won in cash-equivalent assets, and its 35.3 billion won in short-term borrowings is secured by the company's headquarters building, which is currently valued at over 100 billion won, so there should be no major issues."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.